Thymidine phoshorylase as a target for antiangiogenesis treatment

G J Peters1, I V Bijnsdorp, M Fukushima

  • 1Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands. gj.peters@vumc.nl

Insights

Thymidine phosphorylase (TP) drives cancer angiogenesis by breaking down thymidine into sugars that promote cell migration and invasion. Inhibiting TP or its sugar metabolites can block these pro-angiogenic effects.

Area of Science:

  • Biochemistry
  • Cancer Biology
  • Molecular Oncology

Background:

  • Thymidine phosphorylase (TP) is a key enzyme implicated in cancer angiogenesis, the process of new blood vessel formation essential for tumor growth.
  • TP catalyzes thymidine breakdown, producing metabolites like deoxyribose-1-phosphate (dR-1-P) and deoxyribose (dR), which may contribute to angiogenesis.
  • TP is often overexpressed in tumors and associated stromal cells, suggesting a significant role in the tumor microenvironment.

Purpose of the Study:

  • To elucidate the mechanistic link between TP, its enzymatic activity, thymidine metabolites, and cancer angiogenesis.
  • To investigate the role of TP-generated sugars in promoting endothelial cell attraction, invasion, and specific signaling pathways.
  • To evaluate the therapeutic potential of TP inhibition (TPI) in modulating these angiogenic processes.

Main Methods:

  • Utilized cancer cell lines with varying TP expression levels (wild-type and TP-transfected variants).
  • Assessed endothelial cell attraction, invasion, and metabolite formation (dR-1-P, dR, dR-5-P) following thymidine exposure.
  • Investigated TP's impact on signaling pathways (e.g., FAK, p70/S6) and its interaction with mTOR inhibitors (rapamycin).

Main Results:

  • TP expression in cancer cells enhanced endothelial cell attraction, particularly in RT112/TP cells, linked to differential sugar metabolite formation.
  • Thymidine exposure led to rapid dR-1-P formation, subsequent degradation to dR, and accumulation of dR-5-P, with higher levels in RT112/TP cells.
  • TP activation of FAK and p70/S6 signaling pathways was observed, promoting cell migration, and thymidine protected against rapamycin-induced cytotoxicity, an effect reversed by TPI.

Conclusions:

  • TP plays a critical role in promoting cancer angiogenesis and cell migration through its enzymatic activity and the generation of specific sugar metabolites.
  • The study establishes a mechanistic link between TP, thymidine metabolism, key signaling pathways (FAK, mTOR/p70S6K), and enhanced cell migration.
  • Targeting TP and its downstream metabolic and signaling pathways represents a promising strategy for anti-angiogenesis cancer therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...